Academic Journal
Quartile not availableCurrent Opinion in Endocrinology Diabetes and Obesity
About Current Opinion in Endocrinology Diabetes and Obesity
Current Opinion in Endocrinology Diabetes and Obesity is a peer-reviewed scholarly journal published by Lippincott Williams & Wilkins (GB). It focuses on Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins, Adrenal Hormones and Disorders.
Key indicators: ISSN 1752296X, 17522978; H-index 102; 1,498 works indexed; 51,054 citations.
Scope and Subject Areas
The journal covers: Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins, Adrenal Hormones and Disorders, Bone health and osteoporosis research, Diabetes Treatment and Management, Hormonal and reproductive studies, Thyroid Disorders and Treatments, Lipoproteins and Cardiovascular Health.
Journal Metrics
- H-index (102): 102 articles have each received at least 102 citations.
- Works indexed: 1,498 publications tracked in OpenAlex.
- Total citations: 51,054.
- Open Access: No.
Publishing in Current Opinion in Endocrinology Diabetes and Obesity
Researchers should verify the journal's current scope, submission guidelines, and indexing status via the official journal website before submitting. Ensure your manuscript aligns with the journal's subject areas.
Official website: https://journals.lww.com/co-endocrinology/pages/default.aspx
Frequently Asked Questions
What is the ISSN of Current Opinion in Endocrinology Diabetes and Obesity?
1752296X, 17522978.
What subjects does Current Opinion in Endocrinology Diabetes and Obesity cover?
Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins, Adrenal Hormones and Disorders, Bone health and osteoporosis research, Diabetes Treatment and Management.
Who publishes Current Opinion in Endocrinology Diabetes and Obesity?
Lippincott Williams & Wilkins.
Is Current Opinion in Endocrinology Diabetes and Obesity peer-reviewed?
Yes — it is a peer-reviewed scholarly journal.
Journal Metrics
A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Normal weight obesity: a South Asian phenotype
Tahniyah Haq
2026-09-18 · DOI: 10.1097/med.0000000000000979Asthma and female reproductive health: implications for fertility and pregnancy
Viny Kantroo, Bharti Kalra, Shehla Shaikh
2026-09-18 · DOI: 10.1097/med.0000000000000980Editorial introductions
2026-10 · DOI: 10.1097/med.0000000000000975Functional gonadotroph adenomas
Diane Donegan, Dana Erickson
2026-08-13 · DOI: 10.1097/med.0000000000000973Thyroxine withdrawal prior to radioiodine therapy in papillary thyroid carcinoma – current scenarios
Saumya Sunny, Julie Hephzibah
2026-10 · DOI: 10.1097/med.0000000000000977Recent advances in the medical management of thyroid eye disease
Khushboo Agarwal, Vamshi Rao-Waronski, Nihal Thomas, Bijay Vaidya et al.
2026-10 · DOI: 10.1097/med.0000000000000972Single-cell resolution in adrenocortical carcinoma: from pathogenesis to treatment
Dipika R. Mohan, Gary D. Hammer, Antonio Marcondes Lerario
2026-10 · DOI: 10.1097/med.0000000000000974Determining when patients with thyroid illnesses should be cleared for surgery
Anna Paul, Anuka Alena Abraham, Tina George
2026-10 · DOI: 10.1097/med.0000000000000978New horizons for autoimmune hyperthyroidism with FcRn blockers
Fearghas Middleton, Prakash Abraham
2026-10 · DOI: 10.1097/med.0000000000000971Adrenal insufficiency diagnosis: new approaches to indeterminate baseline cortisol
Maria Ortega, Natalia Fretes Oviedo, Ricardo Correa
2026-10 · DOI: 10.1097/med.0000000000000969Updates in systemic therapy for refractory thyroid carcinoma – targeted agents, immunotherapy, and chemotherapy
Josh Thomas Georgy, Harikrishna Kovilapu, Ashish Singh
2026-10 · DOI: 10.1097/med.0000000000000970Functioning pituitary adenomas in pregnancy: updates and controversies
Elena V. Varlamov, Monica L. Gheorghiu, Maria Fleseriu
2026-07-28 · DOI: 10.1097/med.0000000000000968EDITORIAL INTRODUCTION
2026-08 · DOI: 10.1097/med.0000000000000967Exploring the role of parathyroid hormone in sarcopenia: A review
Ana Carolina Vieira Selva, Pushpa Suriyaarachchi, Gustavo Duque
2026-08 · DOI: 10.1097/med.0000000000000963Normocalcemic primary hyperparathyroidism: an update on diagnostic and management challenges
Krupa B. Doshi, Manju Chandran
2026-08 · DOI: 10.1097/med.0000000000000965Prediabetes before pregnancy: implications for risk stratification and research
Saptarshi Bhattacharya, Viswanathan Mohan, Lakshmi Nagendra, Ponnusamy Saravanan et al.
2026-05-20 · DOI: 10.1097/med.0000000000000964Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence
Julien Paccou
2026-08 · DOI: 10.1097/med.0000000000000962Secondary hyperparathyroidism in chronic kidney disease: update on pathophysiology and new treatment targets
Amal Derai, Ditte Hansen, Hanne Skou Jørgensen
2026-08 · DOI: 10.1097/med.0000000000000961Editorial introduction
2026-06 · DOI: 10.1097/med.0000000000000958Parathyroid hormone assays in 2026: second versus third generation, standardization, and clinical interpretation
Niklas Rye Jørgensen, Etienne Cavalier, Samuel D. Vasikaran
2026-08 · DOI: 10.1097/med.0000000000000960Reviews
Community Reviews
Version History
October 10, 2026 at 4:19 am
October 9, 2026